Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of EC0225 for the Treatment of Refractory or Metastatic Tumors

This study has been completed.
Information provided by (Responsible Party):
Endocyte Identifier:
First received: February 27, 2007
Last updated: March 8, 2012
Last verified: March 2012
This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0225 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.

Condition Intervention Phase
Drug: EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)
Drug: 99mTC-EC20 (Folic acid-technetium 99m conjugate)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 3 of a 4-Week Cycle

Resource links provided by NLM:

Further study details as provided by Endocyte:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) [ Time Frame: Dose escalation to the highest dose that can be safely administered to produce acceptable, manageable and reversible toxicity in no more than 0 or 1 of 6 patients ]

Secondary Outcome Measures:
  • Pharmacokinetic and pharmacodynamic parameters [ Time Frame: Obtained during the first cycle of therapy on Days 1 and 3 ]
  • Anti-tumor activity [ Time Frame: Initial dose of study therapy to disease progression ]
  • Uptake of 99mTc-Ec20 in tumors and normal tissues [ Time Frame: 1-2 hours post-administration of 99mTc-EC20 ]
  • Safety and tolerability [ Time Frame: Initiation of study therapy through 30 day post last dose of study therapy ]

Enrollment: 77
Study Start Date: February 2007
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)
    Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
    Other Name: Folic acid desacetylvinblastine hydrazide conjugate
    Drug: 99mTC-EC20 (Folic acid-technetium 99m conjugate)
    20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
    Other Names:
    • Folic acid-technetium 99m conjugate
    • FolateScan
Detailed Description:
This is a Phase 1, dose escalation study of EC0225 administered by intravenous bolus (IV) during weeks 1 and 3 of a 4-week cycle to patients with refractory or metastatic cancer who have exhausted standard therapeutic options. EC0225 is a drug that is specifically designed to enter cells via a folate vitamin receptor. Experimental evidence shows that the target receptor is over-expressed in many human cancers. There are no previous human studies of EC0225; however, lab research (research in test tubes or animals) using EC0225 has shown activity against tumors in animals. This activity in animal models suggests that EC0225 may be useful as chemotherapy against human cancers. The primary objective of this study is to determine the safety and maximum tolerated dose of EC0225 given by intravenous bolus. The efficacy of treatment will also be measured.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Histological or cytological diagnosis of neoplasm
  • No effective standard therapeutic options
  • ECOG performance status of 0-2
  • ≥ to 4 weeks post therapeutic radiation or chemotherapy(≥ to 6 weeks for nitrosureas) and recovery (to baseline status) from associated acute toxicities. Patients previously treated with non-cytotoxic therapy and who have recovered from or have controlled drug-associated toxicity are allowed to enter the trial after a period consisting of 4 half-lives of the agent.
  • Negative serum pregnancy test for women of child-bearing potential within one week prior to treatment with investigational agents (99mTc-EC20 and EC0225)
  • Adequate bone marrow reserve, renal and hepatic function

Exclusion Criteria:

  • Concurrent malignancies
  • Women who are pregnant or lactating
  • Evidence of symptomatic brain metastases
  • Receiving concomitant anticancer therapy (excluding supportive care)
  • Requires palliative radiotherapy at time of study entry
  • Unable to tolerate conditions for radionuclide imaging
  • Administration of another radiopharmaceutical that would interfere with assessment of 99mTc-EC20
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00441870

United States, Maryland
Greenebaum Cancer Center - University of Maryland Medicine
Baltimore, Maryland, United States, 21201
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Nevada
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89135
Sponsors and Collaborators
Study Director: Richard A. Messmann, MD, MHS, MSc Endocyte
  More Information

Responsible Party: Endocyte Identifier: NCT00441870     History of Changes
Other Study ID Numbers: EC-0225-01
Study First Received: February 27, 2007
Last Updated: March 8, 2012

Keywords provided by Endocyte:
Phase 1

Additional relevant MeSH terms:
Folic Acid
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on April 26, 2017